Drug intelligence / Profile preview

CBX-13

Development stage: Preclinical
Lead developer: Cybrexa Therapeutics
Modality: Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration: Intravenous

Overview

CBX-13 is a peptide-drug conjugate (PDC) developed by Cybrexa for oncology indications. It utilizes the proprietary alphalex technology to deliver the highly potent cytotoxic agent maytansine DM4 selectively to tumor cells. The conjugate is designed for enhanced selectivity in HER2-negative solid tumors that are not targetable by other therapies, demonstrating single-digit nanomolar potency in preclinical models. Its mechanism of action involves inhibition of tubulin polymerization, leading to disruption of microtubule dynamics and subsequent cell cycle arrest and apoptosis in cancer cells[2][6][8].

Targets

TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on CBX-13.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBX-13.

Explore the full profile